Fluocinonide Shortage: What Providers and Prescribers Need to Know in 2026

Fluocinonide — a high to super-high potency topical corticosteroid first approved in 1971 — remains a foundational treatment for corticosteroid-responsive dermatoses including plaque psoriasis, atopic dermatitis, and lichen planus. While no formal FDA-declared shortage exists as of 2026, many patients and practices are experiencing real-world availability gaps, particularly for less common formulations. This clinical update summarizes current availability, evidence-based substitution options, and practical support tools for your patients.

Current Availability Status

As of 2026, fluocinonide is not listed on the FDA Drug Shortages Database or the ASHP Current Drug Shortages list. Generic fluocinonide 0.05% cream remains broadly available at most retail pharmacies. The following formulations are most frequently reported by patients as difficult to obtain:

• Fluocinonide 0.05% gel — less commonly stocked; may require special order at many pharmacies
• Fluocinonide 0.05% topical solution — used on the scalp; lower dispensing volumes mean smaller par levels at retail pharmacies
• Fluocinonide 0.1% cream (Vanos-branded or authorized generic) — higher cost limits stocking at some pharmacies

Potency Classification and Substitution Framework

Fluocinonide spans two potency classes depending on concentration:

• Fluocinonide 0.05%: Class II, high potency. Comparable steroids: betamethasone dipropionate 0.05% ointment/cream, desoximetasone 0.25% cream/ointment, halcinonide 0.1% cream.
• Fluocinonide 0.1% (Vanos): Class I, super-high potency. Comparable steroids: clobetasol propionate 0.05%, halobetasol propionate 0.05%, augmented betamethasone dipropionate 0.05% gel/ointment.

Evidence-Based Substitution Recommendations

When fluocinonide is unavailable, consider the following clinically equivalent substitutes based on indication:

Plaque Psoriasis (body):

• Clobetasol propionate 0.05% ointment or cream — Class I; widely available; well-tolerated for short-term use on thick plaques
• Halobetasol propionate 0.05% cream or ointment — Class I; comparable efficacy to clobetasol in plaque psoriasis

Atopic Dermatitis (eczema):

• Betamethasone dipropionate 0.05% cream or ointment — Class I/II; strong evidence base; suitable for moderate to severe AD on body
• Desoximetasone 0.25% cream — Class II; equivalent potency to fluocinonide 0.05%; readily available generic

Scalp Conditions (when fluocinonide solution is unavailable):

• Clobetasol propionate 0.05% shampoo or solution — Class I; designed for scalp use; widely available
• Betamethasone valerate 0.1% lotion — Class III/IV; lower potency but available and appropriate for scalp psoriasis flares

Non-Steroidal Options When Prolonged Treatment Is Needed

For patients who require longer-term management and wish to avoid corticosteroid-related side effects, consider:

• Tacrolimus 0.1% ointment (Protopic): Approved for moderate-severe AD in adults; particularly useful for face, neck, and intertriginous areas where potent TCS are contraindicated
• Roflumilast 0.3% cream (Zoryve): PDE4 inhibitor; approved for plaque psoriasis; once-daily application; non-steroidal
• Tapinarof 1% cream (Vtama): Aryl hydrocarbon receptor agonist; approved for plaque psoriasis in adults; does not carry the systemic corticosteroid risks

Practical Workflow: Supporting Patients With Access Issues

When a patient contacts your office reporting they cannot find fluocinonide, here is an efficient protocol:

1. Direct the patient to medfinder (medfinder.com/providers) — they can enter the prescription details and location, and medfinder will call pharmacies near them to locate stock.
2. If fluocinonide is unavailable after pharmacy outreach, send an e-prescription for the clinically equivalent alternative to the pharmacy that has it in stock.
3. For patients needing ongoing treatment: consider non-steroidal alternatives that do not require short-term use restrictions.

For a provider-facing overview of medfinder and how it can reduce medication access burden for your patients, visit medfinder.com/providers.

Also see our companion guide: How to Help Your Patients Find Fluocinonide in Stock.